Physician profile
Robert J Barnes
NPI 1609840503
$3,098.25
in general payments reported to CMS, 2019-2025
22 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $329 · 2021: $392 · 2022: $305 · 2023: $567 · 2024: $473 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $443.66 | 2019-2025 | Clareon Panoptix Pro, Rocklatan, Argos |
| Aerie Pharmaceuticals, INC. | $396.36 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $381.30 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Abbvie INC. | $370.54 | 2022-2025 | Xen Glaucoma Treatment System, Alphagan P, Lumigan |
| Allergan, INC. | $335.91 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $271.87 | 2019-2021 | |
| Glaukos Corporation | $263.38 | 2023 | |
| Novartis Pharmaceuticals Corporation | $143.93 | 2019-2021 | |
| Oyster Point Pharma, INC. | $80.20 | 2022-2024 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $61.18 | 2024 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $60.13 | 2023-2024 | Veritas Vision System, Catalys System |
| Rxsight INC | $54.67 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Viiv Healthcare Company | $39.38 | 2022 | |
| Sun Pharmaceutical Industries INC. | $28.65 | 2020-2021 | |
| Optos, INC. | $26.16 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $24.70 | 2024 | Oxervate |
| Thea Pharma INC. | $24.11 | 2022 | |
| Shire North American Group INC | $24.00 | 2019 | |
| New World Medical,INC. | $22.97 | 2024 | Streamline, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Akorn, INC. | $16.45 | 2019 | |
| Sight Sciences, INC. | $14.97 | 2022 | |
| Amgen INC. | $13.73 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.